UBS is reportedly in the running to lead the sale of Hirslanden for BC Partners, after having sold the Swiss medical provider to the private equity group three years ago.

The deal, expected to take place next year, could value the company at as much as €2.4bn ($3.2bn) according to a report by Bloomberg. UBS was unavailable for comment.